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and whole saliva
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Abstract 
Background: Pathologically elevated levels of matrix metalloproteinase-8 (MMP-8) and Lactoferrin in oral fluids have 
been associated with the presence of gingivitis/periodontitis. This study aimed to assess the origin of MMP-8 and 
Lactoferrin in periodontitis patients and to identify the degree to which conventional clinical parameters correlate 
with their presence.
Methods: A total of ten periodontitis and ten healthy patients were included in this study. Whole saliva (stimulated 
and unstimulated), parotid/sublingual glandular fluid and gingival crevicular fluid from pockets and sulci were tested 
for MMP-8 and Lactoferrin and protein concentrations were quantified using an ELISA assay. Clinical parameters were 
checked for potential associations with MMP-8 and Lactoferrin levels.
Results: Periodontal patients presented higher concentrations of MMP-8 and Lactoferrin in pockets than other 
sources (P = 0.03). Lactoferrin measurement was higher in the parotid compared to sublingual glandular fluid in peri-
odontitis patients (P = 0.03). Increased probing pocket depth was positively correlated with high MMP-8 and Lactofer-
rin levels.
Conclusions: Periodontal pockets appear to be the major source of active matrix metalloproteinase and Lactofer-
rin, which also may also enter the oral cavity through the salivary glands. Since clinically healthy sites in periodontitis 
patients also had elevated biomarker levels, gingival crevicular fluid biomarker testing may be more predictive of 
future tissue breakdown than conventional clinical parameters.
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Background
Periodontitis is a common inflammatory oral condi-
tion induced by certain periodontal bacterial species 
[1]. These bacteria colonize the non-shedding hard tis-
sue surfaces and when allowed to grow and mature 
develop into biofilms which may trigger an inflammation 
of the periodontal tissues i.e. gingiva, periodontal liga-
ment and alveolar bone [1, 2]. The severity ranges from 
superficial inflammation of the gingiva (gingivitis) to 
extensive destruction of the connective tissue and bone 
(periodontitis), finally leading to tooth loss if untreated 
[2]. The prevalence of periodontitis is high, with an aver-
age impact on 46% of the adult population in developed 
countries and higher incidence in developing nations [3]. 
Peri-implantitis is also considered a periodontitis-like 
Open Access
*Correspondence:  liza.ramenzoni@zzm.uzh.ch
1 Clinic of Conservative and Preventive Dentistry, Center of Dental 
Medicine, University of Zurich, Plattenstrasse 11, 8032 Zurich, Switzerland
Full list of author information is available at the end of the article
Page 2 of 12Ramenzoni et al. BMC Oral Health          (2021) 21:385 
disease process, where similar periodontitis bacterial 
plaque is regarded as its primary etiologic factor in the 
loss implants. In fact, the literature indicates that the 
presence or history of periodontitis may be one of the 
highest risk factors for peri-implantitis [4]. Clinical find-
ings around tooth with periodontitis and failing implants 
include marked gingival inflammation, deep pocket 
formation, and progressive bone loss [4]. As both peri-
odontitis and peri-implantitis have similar inflammatory 
phenotypes when assessed cross-sectionally, treatment 
protocols for peri-implantitis were modeled according to 
those used for periodontitis. Often, periodontal disease is 
not reversable but manageable and scaling root planing 
treatment may be enough to control periodontal infec-
tion, restore oral tissues to good health, and tighten loose 
teeth. The treatment procedures for peri-implantitis are 
also very similar to that of periodontitis, but more intense 
and often surgery based. Treatment for both periodonti-
tis and peri-implantitis, even when successful, will not 
result in a complete regeneration of lost structure. There-
fore, it is crucial to recognize early (subclinical) disease 
activity before its establishment and assess risk for fur-
ther disease progression with further tissue destruction.
At a closer look, the destruction of host tissues in peri-
odontitis and peri-implantitis is caused by an interaction 
between microbial and host factors, which synergisti-
cally allow otherwise protective enzymes, proteins and 
bacteria to modify in ways that become pathogenic and 
beyond the body’s innate ability to hold inflammatory 
destruction at bay [5]. The term “proteome” was coined 
in 1996 to describe the study of changes occurring in the 
oral environment as microorganisms adapt to environ-
mental changes [6]. Since historic periodontal param-
eters of pocket depth, recession and bleeding are signs 
of past destruction, they are of limited value in identify-
ing current (subacute) disease challenges and providing 
tailored preventive therapy to avoid loss of periodontal 
tissue [7–10]. Recognizing these facts, many proteomic 
point-of-care diagnostics biomarkers are being sought to 
proactively determine the presence or absence of peri-
odontal destruction factors [11]. One well-researched 
inflammatory biomarker is matrix metalloproteinases 
8 (MMP-8), also known as collagenase-2 or neutrophil 
collagenase [12–15]. It is a predominant collagenase 
mostly identified in gingival crevicular fluid (GCF) and 
associated with periodontitis severity, especially in acti-
vated/active form (aMMP-8). The major cellular source 
of MMP-8 are polymorphonuclear neutrophils (PMN) 
and increased production levels of aMMP-8 signify the 
progression of gingivitis into periodontitis, with associ-
ated soft tissue destruction [16]. In fact, some authors 
considered MMP-8 as the main collagenase in peri-
odontitis, since 90% to 95% of collagenolytic activity 
in gingival crevicular fluid and saliva is actually derived 
from higher levels of MMP-8 compared to healthy indi-
viduals [12–16]. Consequently, MMP-8 is regarded by 
many studies as one of the most promising biomarkers 
for periodontitis in oral fluids [12–16]. Another key peri-
odontal biomarker is Lactoferrin, which is globular glyco-
protein secreted in response to a bacterial challenge, and 
has also been shown to be strongly associated, especially 
with periodontitis [16, 17]. In fact, some authors identify 
increased levels of Lactoferrin in both unstimulated and 
stimulated saliva in advanced periodontitis patients com-
pared to healthy patients [16–18]. Lactoferrin is known 
to for its ability to bind iron, which removes important 
elements involved in oral bacterial cell growth in saliva 
[16–18]. Thus, Lactoferrin is claimed to have antibacte-
rial activity and low concentrations of Lactoferrin pro-
mote bacterial growth. Periodontal biomarkers, such as 
MMP-8 and Lactoferrin, that are easy to access and can 
be rapidly and non-invasively sampled, would be of a pre-
dictive nature and a great benefit to patients at risk for 
early developing periodontal disease [19].
Saliva and GCF were previously both cited as sources of 
aMMP-8 and Lactoferrin, and fit periodontal collection 
parameters [18–20]. However, saliva is known to have 
multiple contributing sources (parotid, sublingual and 
submandibular glandular fluids, as well as GCF washout) 
[21]. Following the studies on the origin and variation in 
number of polymorphonuclear/leukocytes in the human 
saliva, the gingival crevices are suggested to be the main 
point of entry for PMN and its products into the GCF 
and oral cavity, however another proportion is originated 
from salivary glands [22, 23]. The detection of MMP-8 
in GCF and whole saliva is the most frequently studied 
[21–23]. However, the contributions of salivary glands to 
the MMP-8 enzyme production has not yet been demon-
strated. In fact, whole saliva per se represents a complex 
fluid mixture, and gingival crevice exudate accounts only 
for a part of its composition, while another important 
part comes from major salivary glands [24]. Lactoferrin 
was also shown to be synthesized by exocrine glands and 
neutrophils in infection/inflamed sites [25, 26]. Never-
theless, the data from whole saliva samples has failed to 
reveal the other multiple possible origins of MMP-8 and 
Lactoferrin inflammatory biomarkers in the oral cavity.
Therefore, the aim of the study was not only to deter-
mine the presence of aMMP-8 and Lactoferrin in 
patients newly diagnosed with active chronic periodon-
tal disease, but also to determine the different possible 
sources of these biomarkers (GCF, major salivary glands 
and/or whole saliva, both stimulated and unstimulated). 
We hypothesized that both aMMP-8 and Lactoferrin 
may be originated from different salivary glands, other 
than only oral rinse or GCF, since saliva has multiple 
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other contributing sources. In addition, the associations 
between aMMP-8 and Lactoferrin to clinical parameters 
of periodontitis (i.e. the clinical extent of periodontitis) 
and key deep pocket bacteria were also investigated.
Methods
Participants and study design
A total of ten periodontitis patients (6 men and 4 
women) and ten healthy patients (2 men and 8 women) 
were recruited for this study. New patients referred to the 
University of Zurich, Center of Dental Medicine, Clinic 
of Conservative and Preventive Dentistry for treatment 
of chronic periodontal disease were asked if they would 
volunteer to participate in the study, after having been 
evaluated for their overall treatment needs. The healthy 
patients were similarly recruited. All volunteers were 
informed of the aims and parameters of the study, but 
offered no compensation for participation. Patients were 
provided with informed written consent and notified of 
their right to rescind agreement at any time. The study 
protocol was approved by the Canton of Zurich Ethics 
Committee (BASEC-Nr. 2016-00243), according to the 
Helsinki Declaration. The inclusion criteria were as fol-
lows: patients between the ages of 18 and 75, with gener-
alized chronic periodontitis, who had at least one tooth 
site per quadrant with periodontal probing pocket depths 
(PPD) ≥ 5 mm, bleeding on probing (BOP), plaque index 
(PI) ≥ 20%, clinical attachment Level (CAL) ≥ 3  mm, 
furcation involvement, and radiographical bone assess-
ment. All patients had at least 22 teeth and an untreated 
chronic generalized periodontitis, according to the 
Periodontology Classification of Periodontal Diseases 
and Conditions [1], with more than 30% of tooth sites 
affected (clinically and radiographically). Inclusion crite-
ria for the healthy patients, beside similar age, were no 
history on periodontal disease treatment, probing pocket 
depths (PPD) ≤ 3 mm, mean BOP percentages ≤ 25% and 
no radiographically identified bone loss or CAL. Patients 
of both genders were eligible to participate. The exclusion 
criteria for both test groups were as follows: pregnant 
or nursing women, heavy smokers (> 10 cigarettes/day), 
Wharton’s duct or Stensen’s duct redness, gingival hyper-
trophy, antibiotic or anti-inflammatory therapy within 
the last six months, a history of any systemic disease 
(i.e. immunosuppressed or diabetes patients) affecting 
the outcome of the periodontal therapy and/or any peri-
odontal treatment within the previous six months. Two 
patients (1 man, 1 woman) from the initial periodontal 
group had to be excluded after antibiotic therapy for a 
sinus infection and bladder infection within the previous 
6 months were belatedly reported. In total, ten periodon-
titis patients and ten healthy patients participated in the 
study.
Clinical evaluation
All parameters, anamneses (medical and dental his-
tory) and dental status were obtained by one calibrated 
examiner (D.H.) between September 2018 and Septem-
ber 2019. This evaluation included: decayed, missing 
and filled teeth; tilt or overeruption; mobility and sensi-
tivity [21, 27, 28]. A thorough periodontal examination 
was performed [29] including: assessment of tooth PPD, 
BOP, PI and relative CAL at each site using a manual 
probe (PCP10-SE, Hu-Friedy, Chicago, IL, USA), BOP at 
six sites per tooth, the presence or absence of pus secre-
tion, the presence or absence of gingival recession, the 
presence or absence of furcation, and the presence or 
absence of plaque. Periodontitis was diagnosed according 
to Armitage’s classification whereby clinical attachment 
loss ≥ 3 mm affecting more than 30% of the dentition was 
considered generalized moderate to severe periodontitis 
[1]. Under the new classification system, these patients 
would be classified as having Stadium III, Grade B peri-
odontitis [30]. Those patients meeting the inclusion crite-
ria were asked if they would be interested in participating 
in this study. The study was explained to be noninvasive, 
that their data would be anonymized and that knowledge 
gained would help with our understanding of the sources 
of periodontal inflammation and find simplified meas-
ures for determining its presence before clinical destruc-
tion becomes obvious. Written information about the 
study was provided and patients were asked not to eat, 
smoke, drink or rinse his/her mouth for 1–2  h prior to 
sample collection.
Sample collection
At this appointment, the study was again explained to 
the patient and a signed consent form collected. No 
further probing was undertaken, to avoid falsifying the 
test results due to bleeding. The samples collected were 
in the following order: unstimulated saliva, stimulated 
saliva, saliva directly from the parotid gland, saliva from 
the submandibular gland, GCF from the deepest pocket 
in each quadrant, followed by bacterial sampling with a 
paper point and GFC from a sulcus (healthy site) in each 
quadrant. For the healthy control group, similar sampling 
was undertaken, with the exclusion of pockets.
Unstimulated saliva was collected by placing the patient 
in an upright position with his head inclined forward so 
that the produced saliva could be collected by letting the 
saliva drop into a disposable collection container (Poly-
styrol PS, 30 ml, Semadeni Plastics Group, Ostermundi-
gen, Switzerland) for a period of up to 15  min, until at 
least 3  ml of saliva was produced. Following that, the 
3 ml of stimulated saliva was also collected after asking 
the patient to chew for approximately 5  min on a piece 
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of parafilm film (Bemis Company Inc. Oshkosh, WI, 
USA). To ensure accurate results, the patient was asked 
to swallow the first portion of saliva before collecting 
the sample [31–35]. Finally, 2 ml of saliva from each col-
lection container were transferred using fresh dispos-
able pipettes (PE-LD 3.5  ml, Semadeni Plastics Group, 
Ostermundigen, Switzerland) to individual Eppendorf 
tubes (Eppendorf AG, Hamburg, Germany) for further 
analysis. To gain saliva directly from the saliva producing 
glands, the lips and the cheeks were first isolated from 
teeth and tongue with cotton rolls. The maxillary teeth 
were isolated first and the saliva gently removed from 
the outside of the Stensen’s Duct with the dental unit air 
syringe. Parotid gland fluid was collected by placing a cal-
ibrated volumetric disposable sterile micropipette (mini-
caps, Hirschmann Laborgeräte GmbH & Co., Eberstadt, 
Germany) in contact with the Stensen’s duct orifice for 
1–2 min until the micropipette was filled (~ 50 µl). Like-
wise, the saliva from the sublingual and submandibular 
gland was collected from the Wharton’s duct orifice until 
the micropipette was filled. Once full, each micropipette 
was placed in a separate Eppendorf tube containing pro-
tease inhibitor solution (Sigma-Aldrich, St Louis, MO, 
USA).
For the GCF collection, the immediate area from which 
the sampling was to be done was isolated with cotton 
rolls and kept dry with the dental unit suction attach-
ment (quadrant-wise). The deepest pocket present in 
each quadrant had been previously identified and the 
adjacent tooth was freed of supragingival plaque using 
a cotton pellet. GCF samples were then obtained using 
sterile filter paper strips (Periopaper gingival fluid col-
lection strips, Oraflow, Smithtown, NY, USA) inserted 
into the pocket for 30 s, removed and placed in individ-
ual Eppendorf tubes filled with protease inhibitor solu-
tion as described above. Care was taken to avoid physical 
irritation of the sulcular or junctional epithelia. In case 
the strip of filter paper was contaminated with plaque 
or saliva, the paper was discarded [31–35]. If the filter 
paper showed blood, it was likewise discarded and sam-
pling was repeated at the second deepest pocket in that 
quadrant. As an intrasubject control in the periodontitis 
group, another four GCF samples were collected, one per 
quadrant, from healthy sulci of less than 4 mm probing 
depth without symptoms of gingivitis. Once all samples 
were collected, they were deep freeze stored at − 80  °C 
and thawed for analysis within 6 months of collection.
Finally, microbiological sampling was done by placing 
a sterile paper point (IAI PadoTest, Institut für Ange-
wandte Immunologie IAI AG, Zuchwil, Switzerland) 
in the deepest pocket per quadrant (if bleeding due to 
GCF collection occurred, the second deepest pocket was 
used) for 10 s. All 4 samples were pooled and sent in the 
packaging provided to the company’s external laboratory 
for analysis. This RNA-based assay (IAI Pado Test 4.5) 
tests for Aggregatibacter actinomycetemcomitans (Aa), 
Tannerella forsythia (Tf ), Porphyromonas gingivalis (Pg), 
and Treponema denticola (Td), Prevotella intermedia (Pi) 
and Filifactor alocis (Fa), which are represented in per-
centage (%) if at least one site was revealed positive.
Measurements of the salivary and pockets biomarkers
Samples aliquots from GCF, the major salivary glan-
dular fluids and saliva (stimulated and unstimulated) 
were thawed on ice and centrifuged at 10,000  rpm for 
5–10  min at 4  °C to remove insoluble debris or oral 
mucosal cells from the supernatants. Commercial 
enzyme-linked immunosorbent assay (ELISA) kits were 
used to evaluate levels of aMMP-8 (ab219050) and Lacto-
ferrin (ab200015) following manufacturer’s instructions 
(ELISA kits, Abcam, Cambridge, UK), each at a dilu-
tion of 1:100. The absorbance at 450 nm was accounted 
for each ELISA on a microplate reader (EZ Read 400 
Microplate Reader; Biochrom, Cambourne, UK) and 
the absorbance reference value (540 or 570  nm) was 
subtracted from the test values. Experiments were per-
formed on three specimens from each test group in order 
to confirm the dilution factor of each biomarker. All the 
experiments were conducted in triplicate.
Statistical analysis
The data were explored and summarized using descrip-
tive statistics (mean, standard deviation, median and 
interquartile range) and graphical methods. Due to heter-
oscedastic data, the differences in aMMP-8 and Lactofer-
rin concentrations between the sources (stimulated and 
unstimulated saliva, parotid and submandibular glands, 
pockets and gingival crevicular fluid) were tested pair-
wise using nonparametric Wilcoxon signed-rank tests. 
P-values were adjusted for multiple testing according to 
Holm. Comparisons between the healthy and periodon-
titis group were statistically assessed using Wilcoxon 
rank sum tests. Moreover, potential associations between 
standard clinical parameters, microbial assessments and 
aMMP-8 and Lactoferrin were investigated. All plots and 
tests were calculated with the statistical software R (R 
Core Team, 2018, R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
Clinical evaluation and sample collection
The data of individual recruited participants is listed in 
Table  1. In brief, this study evaluated ten participants, 
30–69  years of age, with periodontitis and ten systemi-
cally and periodontally healthy participants, 17–59 years 
of age. A total of 160 samples (n = 8/subject) were 
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collected for analysis. For periodontitis patients, the 
mean PPD was 7.15  mm, with a range between 5 and 
12  mm and the mean sulcus depth (healthy sites) was 
2.95  mm. For the healthy patients, the mean collective 
sulci was 2.5 mm, with a range between 2 and 3 mm and 
the mean sulcus depth was 2.7 mm. The healthy patients 
exhibited limited BOP, PI with clinical CAL not exceed-
ing 3  mm. The patients with periodontitis exhibited 
higher BOP and PI with generalized CAL ranging from 
6 to 12 mm. Next, the periodontal inflamed surface area 
(PISA) and periodontal epithelial surface area (PESA) 
were recorded on a Microsoft Excel spreadsheet and 
calculated using the formulas previously defined [36]. 
PISA ranged from 22.70   mm2 (≈ 0.2   cm2) in healthy 
individuals, to 5670   mm2 (≈ 56.7   cm2) in patients with 
chronic generalized periodontitis. Further, PESA ranged 
from 1125  mm2 (≈ 11.25   cm2) in healthy individuals, to 
4407  m2 (≈ 44.07  cm2) in patients with chronic general-
ized periodontitis patients.
Measurements of the salivary and pockets biomarkers
Concentration levels (ng/ml) of aMMP-8 and Lacto-
ferrin from the different locations were tested using 
ELISA (Table  2). Pocket depth values less than 4  mm 
are considered as healthy periodontium. Accordingly, 
GCF from sulci (≤ 4 mm) in periodontitis patients were 
evaluated to identify healthy aMMP-8 concentrations. 
One previous study reported that a range of 0–7.4 ng/
ml of aMMP-8 of eluate was found in healthy controls 
[31]. Thus, sites with ≥ 8  ng/mL used here are consid-
ered to indicate sites with breakdown of collagenolytic 
tissue, which shows gingivitis and/or periodontitis-
affected sites.
The results showed that aMMP-8 was above the 
detection limit at all tested sites, in the range of 1.5–
41.5 ng/ml of eluate across all patients. Also, aMMP-8 
levels were found to be significantly higher in the deep 
pockets in periodontitis patients (mean = 34.9  ng/ml) 
compared to all other sources (unstimulated saliva, 
stimulated saliva, parotid, sublingual and GCF from 
sulci, P = 0.03, Fig.  1a). The concentration of aMMP-8 
was significantly lower in healthy patients in all of 
the analyzed sites compared to periodontitis patients 
(P < 0.05 each; Fig.  1a). Lactoferrin was also present 
at all sites in periodontitis patients, in the range of 
121.2–1995.9 ng/ml of eluate. Lactoferrin in periodon-
titis patients was found to be significantly higher in the 
parotid (mean = 1785  ng/ml) compared to sublingual 
glandular fluid (mean = 305.9  ng/ml, P = 0.03). Higher 
values of Lactoferrin were also found in the deep pock-
ets (mean = 1656  ng/ml) compared to GCF from the 
same patients’ sulci (mean = 1252  ng/ml, Fig.  1b). The 
Table 1 Data of individual patients and clinical measurements of PPD, probing pocket depth; BOP, bleeding on probing; PI, plaque 
index; PESA, periodontal epithelial surface area, PISA, periodontal inflamed surface area
Patient Cigarettes/day No. of teeth PPD (mm) BOP PI PISA/PESA
Mean % % mm2
1 0 25 5.2 42 76 2537.2/1222.3
2 1 23 7.2 44 62 5670.1/3422.6
3 10 22 6.5 31 75 2074.1/678.7
4 0 31 8.9 36 78 2086.5/827.5
5 0 30 6.4 48 69 3523.9/2268.9
6 0 24 5.9 46 55 2268.9/2030.2
7 0 29 8.5 79 68 5516.4/4407.7
8 1 26 7.3 62 84 2818.2/1972.9
9 8 28 5.9 54 75 3797.7/2331.3
10 0 26 6.6 31 74 2461.8/925.4
11 3 24 N/A 20 25 28.6/1125.3
12 0 27 N/A 20 25 25.9/1254.3
13 0 30 N/A 24 20 30.2/1599.2
14 0 32 N/A 15 25 25.3/1892.4
15 0 28 N/A 10 15 22.7/1793.3
16 0 28 N/A 15 25 28.9/1299.3
17 0 24 N/A 22 30 26.9/1923.3
18 0 28 N/A 20 27 31.2/2014.2
19 0 28 N/A 25 25 27.9/1892.2
20 0 30 N/A 21 20 28.1/1643.4
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concentration of Lactoferrin was significantly lower in 
healthy patients compared to the periodontitis patients 
in all of the analyzed sites (P < 0.05 each; Fig. 1b).
Additional information to Fig. 1 is seen in Fig. 2, which 
presents the individually shown site-specific concentra-
tions of aMMP-8 and Lactoferrin. The mean site-specific 
concentrations of aMMP-8 and Lactoferrin were found 
to be significantly higher in deeper pockets (P) 1, 2, 3 and 
4 (P1, P2, P3 and P4) compared to sulci (S) 1, 2, 3 and 
4 (S1, S2, S3 and S4) in periodontitis patients (P = 0.002; 
Fig.  2a, b). Further, healthy patients presented signifi-
cantly lower concentrations of aMMP-8 (mean = 3.2 ng/
ml) and Lactoferrin (mean = 507.5  ng/ml) in their sulci 
compared to the sulci of periodontitis patients (aMMP-
8: mean = 15.7 ng/ml), Lactoferrin: mean = 1253 ng/ml).
No association was observed between either aMMP-8 
or Lactoferrin and the subjects’ age, sex, smoking status, 
number of missing teeth, tooth mobility, exudate, CAL or 
bleeding index. In addition, no relationship was evident 
between presence of subgingival microorganisms (Aa, Tf, 
Pg, Td, Pi, Fa) and the levels of aMMP-8 or Lactoferrin. 
However, positive relationships were found between lev-
els of aMMP-8 and PPD, levels of Lactoferrin and PPD 
and MMP-8 and Lactoferrin (Fig. 3a, b).
Discussion
Gold standard clinical parameters, i.e. pocket probing 
and radiographic examination, are widely used in clinical 
practice for identifying established periodontitis disease, 
but the early detection efficacy and/or disease prediction 
using these methods remain inconclusive. Noninvasive 
detection of salivary biomarkers, such as aMMP-8 and 
Lactoferrin, may provide a helpful solution to determine 
early disease manifestation and predict the likelihood of 
future periodontal breakdown, as they have been found 
to be increased enzymes in established advanced perio-
dontal disease [18, 19]. Since the biological phenotype of 
the periodontitis patient is neither properly reflected by 
the clinical assessment methods nor show host response 
with subsequent inflammatory burden, an early biomark-
ers detection may lead to a more successful treatment, 
which shows its clinical significance for patients [18]. In 
fact, periodontal patients who get treatment for perio-
dontitis in its earliest stages generally find that the inter-
ventions are less invasive and disruptive.
Although several studies have correlated biomarkers 
with periodontitis and its progression [37, 38], the actual 
route(s) by which these biomarker enzymes find their 
way into saliva have not been assessed yet according to 
Table 2 Concentrations of aMMP-8 and lactoferrin in sulci and deep pockets
aMMP-8: active matrix metalloproteinase-8





Mean pockets Mean Sulci % ≥ 8 a Mean pockets Mean Sulci % ≥  8a
1 26.03 21.78 78.60 1763.70 1324.10 49.30
2 31.42 21.05 75.20 1748.50 1323.30 52.30
3 37.77 16.82 46.50 1709.90 1270.30 61.90
4 36.67 14.36 29.60 1740.30 1150.40 58.80
5 37.17 15.02 45.30 1694.30 1232.70 42.10
6 34.54 13.89 58.30 1701.60 1279.75 35.90
7 34.64 15.11 44.30 1679.90 1339.25 45.80
8 39.04 13.33 36.50 1728.20 1274.75 65.80
9 36.33 13.57 48.60 1428.70 1191.40 34.60
10 35.35 13.24 58.60 1365.20 1130.05 57.30
11 N/A 5.34 N/A N/A 508.6 N/A
12 N/A 4.78 N/A N/A 509.2 N/A
13 N/A 5.24 N/A N/A 510.5 N/A
14 N/A 5.78 N/A N/A 507.2 N/A
15 N/A 5.29 N/A N/A 510.9 N/A
16 N/A 4.91 N/A N/A 509.3 N/A
17 N/A 4.72 N/A N/A 508.8 N/A
18 N/A 4.71 N/A N/A 510.1 N/A
19 N/A 4.97 N/A N/A 511.9 N/A
20 N/A 5.12 N/A N/A 505.9 N/A
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Fig. 1 Concentration levels of a aMMP-8 (ng/ml) and b Lactoferrin (ng/ml), from all sites tested: unstimulated saliva, stimulated saliva, parotid, 
sublingual, pockets and GCF in both healthy and periodontitis patients. *P < 0.05
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the authors’ knowledge. And as source of any oral bio-
marker should be taken into account when analyzing its 
function, and MMP-8 and Lactoferrin could possibly be 
derived from a number of different sources including 
GCF as well as secretion from salivary glands. Whole 
saliva represents a complex fluid mixture, and gingival 
crevice exudate accounts only for a part of its composi-
tion, while another important part comes from major 
Fig. 2 Site-specific correlations of aMMP-8 (a) and Lactoferrin (b). Boxplots demonstrating the levels of a aMMP-8 (ng/ml) and b Lactoferrin (ng/ml) 
total protein for each individual deep pocket (P1–P4) and sulcus (S1-S4) tested in healthy and periodontitis patients. *P < 0.05
Page 9 of 12Ramenzoni et al. BMC Oral Health          (2021) 21:385  
Fig. 3 Site-level measurements of MMP-8 (a) and Lactoferrin (b) of aMMP-8 versus probing pocket depth (PPD)
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salivary glands [14–34]. In addition, the flow rate fluctu-
ates during the day and depends strongly on the stimuli 
affecting the salivary glands, which may dictate the con-
centration of its constituents such as MMPs. MMP-8 is 
considered one of the main collagenases related to con-
nective tissue and alveolar bone destruction and it is 
considered a crucial mediator of established irreversible 
periodontal disease [37–39]. Active MMP-8 found in 
saliva has been used as the biomarker for point-of-care 
devices for periodontitis, as increases in its level is cor-
related with severity and status of periodontitis [27, 
37–40]. Active MMP-8 in GCF has also been shown to 
be a potential marker for site-specific diagnosis in order 
to evaluate the periodontal treatment response [28]. The 
results of this study demonstrated similar concentrations 
of aMMP-8 in the parotid and sublingual/submandibular 
glandular fluids. However, these levels were overall the 
lowest found and significantly lower than the concentra-
tions in unstimulated saliva, sulcus GCF and stimulated 
saliva. The highest mean concentrations were found in 
the periodontal pockets compared to healthy patients. 
These results indeed highlighted the periodontally dis-
eased pocket as the main source of aMMP-8. One pos-
sible explanation of elevated concentrations of aMMP-8 
in saliva, well beyond that found in the saliva’s sources 
(parotid and submandibular glands), is that through the 
chewing motion associated with the collection of stimu-
lated saliva, sufficient quantities of aMMP-8-containing 
GCF may be released into the saliva. Ultimately, the 
saliva can provide a simple painless source for collect-
ing and testing for aMMP-8. Further, these findings cor-
roborate previous studies that identified aMMP-8 in deep 
pockets and as one of the metalloproteinases that actively 
participate in the degradation of matrix proteins and 
destruction of connective tissue and alveolar bone dur-
ing progression of periodontitis [14, 27, 28, 31]. And also 
confirms that most collagenases in saliva appears to be 
originated from polymorphonuclear leukocytes entering 
the oral cavity through the gingival sulcus [28].
Lactoferrin is a ubiquitous iron-binding protein com-
ponent of the saliva that is present in secondary gran-
ules of polymorphonuclear leukocytes and it is mainly 
produced in the acute phase of periodontitis [41]. In this 
study, the levels of Lactoferrin provided a different pic-
ture than that of aMMP-8. The highest concentrations, 
interestingly, were found in the parotid gland samples, 
followed by deep pockets and gingival sulci. The sublin-
gual glandular fluid, in contrast, displayed significantly 
lower levels of Lactoferrin. As in previous studies, the 
concentration of biomarkers in the oral cavity may be 
related to the glandular fluid composition of saliva [42]. 
In fact, another study showed that unstimulated saliva 
is mainly produced in the submandibular gland (70%), 
followed by parotid (20%) and sublingual glands (2%), 
while stimulated saliva is mostly produced by the parotid 
glands (60%) and submandibular gland (30%) [42]. Higher 
fluid contribution from the parotid to stimulated saliva 
production, however, does not explain the fact that both 
stimulated and unstimulated saliva showed the lowest 
concentrations of Lactoferrin overall. As an iron-binding 
glycoprotein produced by salivary glands, Lactoferrin has 
been shown in a previous study to have been released in 
higher concentrations during an acute phase of gingival 
inflammation and was readily detected in saliva from 
periodontal disease patients [43]. Nevertheless, according 
to the findings of this study, saliva does not appear to be 
the best source for testing the presence of Lactoferrin as 
a biomarker for periodontitis. Our findings found higher 
levels of Lactoferrin in GCF than in saliva. Several studies 
have also previously identified high levels of Lactoferrin 
in the GCF of patients with periodontitis and these levels 
were associated with elevated PPD [41–44]. Even though 
some fluctuations in the levels of biomarkers were seen in 
other studies [45], overall, the levels of biomarkers found 
in the present study were within similar ranges to previ-
ously reported [46].
This study has taken a step in determining the main 
source of major biomarkers related to periodontal dis-
ease determination and progression. One may consider 
a limitation of this study to be the sample size. Practical 
factors played a large role in the relatively small sample 
size. Despite recruitment running over a 1-year period, 
only a limited number of patients were willing to burden 
themselves with an additional clinical appointment to 
participate in the study. However, considering the num-
ber of sites tested and using a “intrasubject design”, our 
data provided meaningful results in this limited study 
population. In fact, the results presented here were 
quite homogenous. However, future larger scale stud-
ies should consider testing GCF for these biomarkers in 
a cohort that would not have any scheduling hardship 
when participating (e.g. dental hygiene recall population) 
over a longer time period (regularly scheduled recall 
appointments).
Conclusions
We conclude that aMMP-8 and Lactoferrin, in combina-
tion, may be useful as diagnostic and predictive adjunctive 
biomarkers for periodontitis. High levels of these biomark-
ers were detected in samples taken from pockets of peri-
odontitis patients. Further, both aMMP-8 and Lactoferrin 
were elevated in the sites considered being clinically healthy 
in periodontitis patients. Even though Lactoferrin was pre-
sent in the GCF (sulci) and parotid gland fluids of healthy 
subjects, the concentrations were significantly lower than 
in the GCF of periodontitis patients. Both aMMP8 and 
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Lactoferrin were shown in this study to enter the oral cav-
ity through the gingival sulcus and salivary glands. Further 
large-scale studies with long-term follow-up to confirm the 
potential of these biomarkers to predict future, preclinical, 
inflammatory processes are still needed.
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